Clinical Research Papers:
Comparing children and adults with medulloblastoma: a SEER based analysis
PDF | HTML | How to cite
Metrics: PDF 1526 views | HTML 2044 views | ?
Qian Li1, Zhenguo Dai2, Yuze Cao1 and Lihua Wang1
1Department of Neurology, The Second Affiliated Hospital, Harbin Medical University, Harbin 150081, Heilongjiang, China
2Department of Cardiology, The Second Affiliated Hospital, Harbin Medical University, Harbin 150081, Heilongjiang, China
Lihua Wang, email: [email protected]
Keywords: medulloblastoma; SEER; survival; treatment; prognostic factors
Received: June 08, 2017 Accepted: December 26, 2017 Published: July 10, 2018
Medulloblastoma (MB) is a brain malignancy, which commonly occurs in children, but is rare in adults. The Surveillance, Epidemiology, and End Results (SEER) database was used to compare survival, clinical features, and prognostic factors of children and adults with MB from 1992 to 2013. Overall survival estimates were compared using the Kaplan–Meier method, and Cox Proportion Hazard Regression modeling was used to evaluate prognostic variables. We identified 616 children (63.8%) and 349 adults (36.2%) with diagnosis of MB. The estimated survival rates for children diagnosed with MB for 2, 5, and 10 years were 85.6%, 75.5%, and 67.9%, respectively; the corresponding estimates for adults were 84.9%, 74.2%, and 67.3%. Radiotherapy was the only identical prognostic factor observed in the two groups. Children MB patients were more likely to experience distal metastases that was associated with increased hazard of mortality, and be diagnosed after 2003. Among adult MB patients, gross total resection (GTR) was a favorable prognostic factor, while large cell/anaplastic (LC/A) histology was correlated with decreased survival. Our analysis highlighted that both groups had similar overall survival time, but the prognostic factors were not comparable, except radiotherapy which was associated with better survival.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.